Patent ID: 8222033

Claim:
A method for producing a pharmaceutical composition comprising human Tr1-like regulatory cells which comprises: (i) activating CD4 + CD25 + T cells to produce activated CD4 + CD25 + T cells by subjecting unactivated CD4 + CD25 + T cells to an activation stimulus selected from the group consisting of (a) and (b), wherein (a) is a combination of plate-bound anti-CD3 and soluble anti-CD28 antibodies; and (b) are allogeneic mature dendritic cells; (ii) anergizing CD4 + CD25 − T cells by contacting the CD4 + CD25 − T cells ex vivo with an anergic state inducing agent consisting of said activated CD4 + CD25 + T cells and said activation stimulus to yield human Tr1-like regulatory cells from said CD4 + CD25 − T cells; and thereafter (iii) formulating a pharmaceutical composition comprising said human Tr1-like regulatory cells.